Alice’s Arc co-signs letter to change EU law to force pharmaceutical companies to trial cancer drugs in children

Alice’s Arc co-signed this letter in conjunction with the Institute of Cancer Research and various other charities to lobby for changes in the current EU legislation to ensure new cancer drugs are used in the treatment of childhood cancers. Since 2012, the current legislation has meant that children have been prevented from trialling 33 new cancer drugs that have come to market. As children’s cancers are rare there is little financial incentive for companies to develop drugs for them. The letter attracted a great deal of media interest including The Guardian, The BBC and The Independent.


Read all the latest fundraising news, charity news and commentary on childhood cancer.

Sara Wakeling is a patient advocate on the Cancer Grand Challenge, NexTGen.
Delighted to be invited as speakers representing the parental perspective of rhabdomyosarcoma.
Please consider participating in a research interview as part of the REFoRMS (Relapsed and Refractory Rhabdomyosarcoma) study, led by the University of York.